Material and Methods:
A clinical audit of case records of cervical cancer treated at our centre in the year 2010 was analysed. Out of the 306 patients evaluated for Cervical Cancer, case records for demographics, treatment methodology, long term toxicity and survival data was analysed using the SPSS. The variables were compared using the Chi-square test, the survival by Log-Rank test.
Results: Out of a total of 306 patients with a median age group of 50 years (range-30-80) evaluated for various symptoms pertaining to cervical cancer, 204 underwent concurrent chemoradiation and 102 patients received only radiation alone. In the total cohort, FIGO stage grouping was stage II in 36% (n=111), stage III in 56% (n=172) and stage IVA in the remaining. Radiation was delivered to a dose of 75Gy to point A, external beam radiotherapy (dose of 45-50Gy) being delivered predominantly on the Telecobalt and followed with low dose rate brachytherapy. Cisplatin based concurrent chemotherapy was delivered as weekly at a dose of 40 mg/sqm in 76% of the patients, while in the rest it was delivered as three-weekly regimen. In the weekly chemotherapy arm, 70% of them received atleast 4 cycles. Median overall treatment time (OTT) was 8.4 weeks (40-95 days). At a median follow up of 36 months, 5 year overall survival in the entire cohort was 30%. The OS in the concurrent chemo radiation arm was better (34% Vs. 29%, p=0.036). The OS in the two chemotherapy arms did not show a difference (log rank, p= 0.46). The survival difference between the two stage groups demonstrated a superior outcome in patients with stage II (40% vs 32%, p= <0.05). Multivariate analysis showed stage, type of chemotherapy and overall treatment (OTT) time were significant for OS. Acute hematologic, GI, GU and skin toxicity was higher in chemoradiation arm. Difference in long term toxicity between the two treatment arms was not statistically significant.
Conclusion:
Our clinical audit of cervical cancer cases treated at our cancer centre, although demonstrates slight inferior survival outcome compared to available literature, might be accounted for the lower Point A dose, longer overall treatment time, and suboptimal chemotherapy dose. These factors have been taken care in our current clinical practice. Purpose or Objective: Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, affecting 40,000 women/year. Recent studies have shown the therapeutic benefit of pelvic lymphnode dissection in order to determine the extent of desease and establish adiuvant therapies. Several trials have also shown that adiuvant radiotherapy(RT) in early stage EC reduces the risk of local recurrence without improving overall survival (OS). However the role of both lymphnode dissection and adiuvant RT in high risk early stage EC is not clearly defined. The aim of our retrospective study is to evaluate the validity of linfadenectomy with intravaginal brachiterapy (IVRT) as therapeutic option in high risk early stage EC, compare it with adjuvant external beam radiotherapy (EBRT) and determine which one determine the best results in terms of Reccurrence Free Survival (RFS) and OS.
Material and Methods:
Were evalueted 85 patients with EC treated between January 2007 and January 2012 with 36 months of follow-up. Of these, 47 had low risk early stage (G1 with myometrial infiltration less than 50% or G2 with myometrial infiltration less than one third ) treated with bilateral histerosalpingovariectomy without any adjuvant therapy; 38 were patients with high risk early stage (G1 with more than 50% of myometrial invasion, G2 with more than one third of myometrial infltration and G3) treated with bilateral hysterosalpingo-oophorectomy and then submitted to pelvic lymphadenectomy (n. 22 pts) plus IVRT or EBRT (n. 16 pts) based on age, comorbidities, tumor grade, histotype, tumor size, presence of lymphovascular invasion space, depth or myometrial infiltration.
Results:
The recurrence rate was respectively of 4% (n.2 pts) among the low risk patients with a RFS of 96% and of 19% (n.11 pts) among the high risk patients with a RFS of 81%. Considering the high risk group, the 45% of recurrence (n.5pts) occurred among patients treated with EBRT and the 55%(n.6pts) among those who received lymphadenectomy with IVRT. The mortality rate was respectively 0% (n.0 pts) among patients treated with EBRT and 0% (n.0 pts) among those who received lymphadenectomy with IVRT.
Conclusion:
Our study shows that in high risk early stage EC there is no significant difference in terms of RFS among patients who received pelvic lymphadenectomy with IVRT and those which had been treated with EBRT. There was also no statistically significant difference for OS between the two groups.
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Material and Methods:
Between November 2008 and March 2015, a total of 36 patients with primarycervical cancer cervical cancer, FIGO stage IB1 to IIIB, confirmed by histology, negative para-aortic lymph nodes were enrolled into this phase I / II trial. Chemotherapy agents were ________________________________________________________________________________ administered in escalating doses to cohorts of three patients at each dose level. Phase II was then assessed at the selected maximum tolerated dose (MTD). The patients were monitored for acute toxicity using the Common Toxicity Criteria, version 3.0 and late toxicity using the RTOG/EORTC.tween November 2008 and March 2015, a total of 36 patients with primary carcinoma of the cervix, FIGO stage IB1 to IIIB, confirmed by histology, negative para-aortic lymph nodes were enrolled into this phase I / II trial. Chemotherapy agents were administered in escalating doses to cohorts of three patients at each dose level. Phase II was then assessed at the selected maximum tolerated dose (MTD). The patients were monitored for acute toxicity using the Common Toxicity Criteria, version 3.0 and late toxicity using the RTOG/EORTC.
Results:
Of the 36 patients, 18 enrolled on phase I study. The MTD was confirmed to be paclitaxel 40mg/m2 and cisplatin 40mg/m2 administered weekly for six cycles with 3D conformal external beam radiotherapy. There were additional 18 evaluable patients for the phase II analysis，yielding a total of 21 patients at the MTD. 3° (9/21) hematologic, principally neutropenia, occurs late cycles. All patients finished 5-6 cycles chemotherapy and radiotherapy in 7 weeks. The median follow-up was 24 months (5-58). At 4 months, 18 CR (1 pCR), 3 PR. At 24 months local control rate was 90.4 %（19/21）. 18/21 patients (85.7％) are still survive ( 1 was loss of follow-up). 2 of 2 recurrent or metastasis patients have died. Late toxicities did not appear during follow-up.
Conclusion:
Combination PTX and DDP administered concurrently with pelvic EBRT can be safely administered at the MTD of DDP 40 mg/m2 and PTX 40 mg/m2 weekly for six cycles in Chinese women. Primary result showed a good clinical outcome. We need continue follow-up. Further development to determine if the combination will help yield a survival benefit.
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